Status:
RECRUITING
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Conditions:
Solid Tumor, Adult
Hepatocellular Carcinoma
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
Detailed Description
The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.
Eligibility Criteria
Inclusion
- Recurrent/Refractory advanced solid tumors
- Age between 18 and 85 years
- Expected life expectancy is greater than three months
Exclusion
- Benign tumor
- Life expectancy is less than three months
- Serious medical commodities
- others
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2037
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04803318
Start Date
January 1 2021
End Date
January 1 2037
Last Update
June 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260